FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:127 January 12, 1995 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: In the study by Lichtiger et al. (June 30 issue),¹ we were surprised by the high frequency of neurologic side effects in the cyclosporine-treated patients. In a review of 3000 recipients of kidney transplants and 800 recipients of bone marrow transplants treated with cyclosporine, the incidence of seizures was 1.5 percent and 5.5 percent, respectively.² As Lichtiger et al. suggest, cyclosporine neurotoxicity may be related to hypocholesterolemia or hypomagnesemia; other postulated mechanisms include hypertension and increased permeability of the blood–brain barrier. Of special interest is the possible toxicity of the solvent in which cyclosporine is provided or . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.